{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-055682","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.059914+00:00","generated_at":"2026-05-16T13:58:54.318078+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas reports preclinical data showing ARV-393 + glofitamab combo yields up to 91% TGI in lymphoma model","bullets":["ARV-393 (3 mg/kg) + glofitamab achieved 81% TGI (concomitant) and 91% TGI (sequential) vs 38% and 36% single-agent.","At 6 mg/kg ARV-393 combo, tumor regressions in 10/10 mice (concomitant) and 7/8 (sequential) vs 5/11 and 0/11 alone.","RNA-seq showed ARV-393 upregulated CD20, interferon signaling, antigen presentation; downregulated proliferation genes.","Phase 1 trial of ARV-393 in relapsed/refractory non-Hodgkin lymphoma ongoing; clinical data due at medical congress in 2026.","Company plans to add glofitamab combination cohort in DLBCL to ongoing Phase 1 trial in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-055682","json":"https://secwatch.observer/filing/0001628280-25-055682.json","markdown":"https://secwatch.observer/filing/0001628280-25-055682.md","text":"https://secwatch.observer/filing/0001628280-25-055682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025055682/0001628280-25-055682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025055682/arvn-20251206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:58:54.318078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}